201 injury found – What does it mean for First Solar?
John Newman continues to expect NDA in 2018 for bremelanotide, while pipeline moves forward.
CFO Paul Herendeen sought out to convince investors to put their money into the long game.
Ram Selvaraju slashes his target to $8 on slower Trulance ramp.
Could Versartis recover after today’s big decline?
Michael Walkley revisits Nokia from the sidelines following LG patent ruling.
Just before the weekend hits, Maxim’s Nehal Chokshi shares thoughts on his top tech picks: AAPL and NTNX.
A glimpse into recent investor meetings with management of Kratos Defense & Security.
A ‘game over’ for Versartis’ somavaratan; A powerful boost for Ascendis’ TC-hGH.
Intercept Sank 40% in September following Dear Doctor and FDA warning letters; Ritu Baral weighs in.